BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26762898)

  • 21. [Immunohistochemical patterns of follicular dendritic cell meshwork and Ki-67 in small B-cell lymphomas].
    Shi YF; Li XH
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):222-6. PubMed ID: 23928527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of Sox11 transcription factor in different types of B-cell lymphomas].
    Zhang WM; Wang C; Li BZ
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):698-9. PubMed ID: 22321551
    [No Abstract]   [Full Text] [Related]  

  • 23. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.
    Mozos A; Royo C; Hartmann E; De Jong D; Baró C; Valera A; Fu K; Weisenburger DD; Delabie J; Chuang SS; Jaffe ES; Ruiz-Marcellan C; Dave S; Rimsza L; Braziel R; Gascoyne RD; Solé F; López-Guillermo A; Colomer D; Staudt LM; Rosenwald A; Ott G; Jares P; Campo E
    Haematologica; 2009 Nov; 94(11):1555-62. PubMed ID: 19880778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma.
    Wang X; Björklund S; Wasik AM; Grandien A; Andersson P; Kimby E; Dahlman-Wright K; Zhao C; Christensson B; Sander B
    PLoS One; 2010 Nov; 5(11):e14085. PubMed ID: 21124928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.
    Ribera-Cortada I; Martinez D; Amador V; Royo C; Navarro A; Beà S; Gine E; de Leval L; Serrano S; Wotherspoon A; Colomer D; Martinez A; Campo E
    Mod Pathol; 2015 Nov; 28(11):1435-47. PubMed ID: 26360498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.
    Salaverria I; Royo C; Carvajal-Cuenca A; Clot G; Navarro A; Valera A; Song JY; Woroniecka R; Rymkiewicz G; Klapper W; Hartmann EM; Sujobert P; Wlodarska I; Ferry JA; Gaulard P; Ott G; Rosenwald A; Lopez-Guillermo A; Quintanilla-Martinez L; Harris NL; Jaffe ES; Siebert R; Campo E; Beà S
    Blood; 2013 Feb; 121(8):1394-402. PubMed ID: 23255553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evaluation of the biological behavior and grade among cases with mantle cell lymphoma.
    Hashimoto Y; Nakamura N; Kuze T; Abe M
    Leuk Lymphoma; 2002 Mar; 43(3):523-30. PubMed ID: 12002755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11.
    Zhou K; Feng X; Wang Y; Liu Y; Tian L; Zuo W; Yi S; Wei X; Song Y; Qiu L
    Exp Hematol; 2018 Feb; 58():27-34.e1. PubMed ID: 29158064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression.
    Wasik AM; Lord M; Wang X; Zong F; Andersson P; Kimby E; Christensson B; Karimi M; Sander B
    Sci Rep; 2013; 3():1400. PubMed ID: 23466598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relationship of Expression Between SOX11 and PAX5 in Pathological Tissue Specimens of Patients with Mantle Cell Lymphoma and Its Clinical Significance].
    Jing CX; Feng Y; Cao X; Xu CG
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):355-360. PubMed ID: 32543142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.
    Nygren L; Baumgartner Wennerholm S; Klimkowska M; Christensson B; Kimby E; Sander B
    Blood; 2012 May; 119(18):4215-23. PubMed ID: 22431568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SOX11 augments BCR signaling to drive MCL-like tumor development.
    Kuo PY; Jatiani SS; Rahman AH; Edwards D; Jiang Z; Ahr K; Perumal D; Leshchenko VV; Brody J; Shaknovich R; Ye BH; Parekh S
    Blood; 2018 May; 131(20):2247-2255. PubMed ID: 29615403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly sensitive and specific
    Federmann B; Frauenfeld L; Pertsch H; Borgmann V; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
    Haematologica; 2020 Mar; 105(3):754-764. PubMed ID: 31296581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mantle Cell Lymphoma With Mantle Zone Growth Pattern.
    Yuan J; Li S; Liu X; Su RJ; Chen M; Wu X; Zheng G; Smith LM; Wang L; Li Y; Liu C; Zhou J; Shen Q; Zhang L; Wang E; Xu ML; Pan Z
    Am J Clin Pathol; 2019 Jul; 152(2):132-145. PubMed ID: 31140550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.
    Szostakowska M; Szymczyk M; Badowska K; Tudek B; Fabisiewicz A
    Med Oncol; 2018 Mar; 35(4):49. PubMed ID: 29520657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma.
    Soldini D; Valera A; Solé C; Palomero J; Amador V; Martin-Subero JI; Ribera-Cortada I; Royo C; Salaverria I; Beà S; Gonzalvo E; Johannesson H; Herrera M; Colomo L; Martinez A; Campo E
    Am J Surg Pathol; 2014 Jan; 38(1):86-93. PubMed ID: 24145648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SOX11 as a minimal residual disease marker for Mantle cell lymphoma.
    Simonsen AT; Sørensen CD; Ebbesen LH; Bødker JS; Bentzen HH; Nyvold CG
    Leuk Res; 2014 Aug; 38(8):918-24. PubMed ID: 24878000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanded clinical and experimental use of SOX11 - using a monoclonal antibody.
    Nordström L; Andréasson U; Jerkeman M; Dictor M; Borrebaeck C; Ek S
    BMC Cancer; 2012 Jun; 12():269. PubMed ID: 22738398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of SOX11 in mantle cell lymphoma.
    Lu TX; Li JY; Xu W
    Leuk Res; 2013 Nov; 37(11):1412-9. PubMed ID: 24001358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.
    Wu B; Li J; Wang H; Wu Q; Liu H
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2197-2208. PubMed ID: 32040593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.